Celldex Therapeutics, Inc. (CLDX) capitalization

Current snapshot

Market Cap
$2.49B
78.5M shares × $31.72 · as of last filing 2026-03-31
Net Worth
$456.2M
Stockholders' equity · 2026-03-31
Enterprise Value
$2.04B
Market cap + debt − cash
Net Debt
-$449.6M
Debt $1.9M − Cash $451.5M

Annual history

One row per fiscal year (10-K). Market cap uses split-adjusted closing price on the fiscal-year-end date × shares outstanding.

Period End Market Cap
FY'25 2025-12-31 $1.80B
FY'24 2024-12-31 $1.63B
FY'23 2023-12-31 $1.92B
FY'22 2022-12-31 $2.09B
FY'21 2021-12-31 $1.66B
FY'20 2020-12-31 $519.3M
FY'19 2019-12-31 $32.4M
FY'18 2018-12-31
FY'17 2017-12-31
FY'16 2016-12-31 $426.6M
FY'15 2015-12-31 $1.55B
FY'14 2014-12-31 $1.64B
FY'13 2013-12-31 $2.16B
FY'12 2012-12-31 $431.9M
FY'11 2011-12-31
FY'11 2010-12-31
FY'11 2009-12-31

Quarterly history

One row per quarter (10-Q and Q4 from 10-K). Market cap uses split-adjusted closing price on the quarter-end date × shares outstanding.

Period End Market Cap
Q1'26 2026-03-31 $2.11B
Q4'25 2025-12-31 $1.81B
Q3'25 2025-09-30 $1.72B
Q2'25 2025-06-30 $1.35B
Q1'25 2025-03-31 $1.20B
Q4'24 2024-12-31 $1.68B
Q3'24 2024-09-30 $2.25B
Q2'24 2024-06-30 $2.44B
Q1'24 2024-03-31 $2.47B
Q4'23 2023-12-31 $2.22B
Q3'23 2023-09-30 $1.30B
Q2'23 2023-06-30 $1.60B
Q1'23 2023-03-31 $1.70B
Q4'22 2022-12-31 $2.10B
Q3'22 2022-09-30 $1.32B
Q2'22 2022-06-30 $1.26B
Q1'22 2022-03-31 $1.59B
Q4'21 2021-12-31 $1.81B
Q3'21 2021-09-30 $2.45B
Q2'21 2021-06-30 $1.32B
Q1'21 2021-03-31 $816.0M
Q4'20 2020-12-31 $693.9M
Q3'20 2020-09-30 $586.7M
Q2'20 2020-06-30 $508.2M
Q1'20 2020-03-31 $29.4M
Q4'19 2019-12-31 $37.8M
Q3'19 2019-09-30 $33.9M
Q2'19 2019-06-30 $39.7M
Q1'19 2019-03-31 $63.2M
Q4'18 2018-12-31
Q3'18 2018-09-30 $75.9M
Q2'18 2018-06-30 $78.3M
Q1'18 2018-03-31 $334.0M
Q4'17 2017-12-31
Q3'17 2017-09-30 $377.8M
Q2'17 2017-06-30 $314.7M
Q1'17 2017-03-31 $448.3M
Q4'16 2016-12-31 $426.6M
Q3'16 2016-09-30 $409.0M
Q2'16 2016-06-30 $436.3M
Q1'16 2016-03-31 $373.2M
Q4'15 2015-12-31 $1.55B
Q3'15 2015-09-30 $1.04B
Q2'15 2015-06-30 $2.49B
Q1'15 2015-03-31 $2.74B
Q4'14 2014-12-31 $1.64B
Q3'14 2014-09-30 $1.16B
Q2'14 2014-06-30 $1.46B
Q1'14 2014-03-31 $1.58B
Q4'13 2013-12-31 $2.16B
Q3'13 2013-09-30 $2.87B
Q2'13 2013-06-30 $1.26B
Q1'13 2013-03-31 $936.5M
Q4'12 2012-12-31 $431.9M
Q3'12 2012-09-30 $383.1M
Q2'12 2012-06-30
Q1'12 2012-03-31
Q4'11 2011-12-31
Q3'11 2011-09-30
Q2'11 2011-06-30
Q1'12 2011-03-31
Q4'11 2010-12-31
Q3'11 2010-09-30
Q2'11 2010-06-30

Methodology

Every figure on this page traces back to SEC EDGAR XBRL company-facts filings (CLDX CIK 0000744218), tagged with the us-gaap and dei taxonomies. Filing-anchored figures are rendered server-side: the market cap and enterprise value tiles use the split-adjusted close on the latest reported period-end × shares outstanding, so they reconcile with the equity / debt / cash figures from that same filing. The two price-anchored tiles (market cap + enterprise value) re-anchor on the most recent daily close in the browser when JavaScript is enabled; shares outstanding and debt / cash stay filing-anchored, so the EV bridge still uses the latest statement of financial position. Historical share prices come from our total-returns daily history (split-adjusted); historical market caps are calibrated against today's share count to correct for SEC retroactive split restatements.

For the exact XBRL concepts and formulas, see the methodology reference for net worth, debt, cash, market cap, enterprise value, net debt, shares outstanding, and the historical-market-cap calibration.

Related tickers

BAC

BANK OF AMERICA CORP /DE/

HUMA

Humacyte, Inc.

RNGR

RANGER ENERGY SERVICES, INC.